



February 28, 2020

Vermont Attorney General's Office  
109 State Street  
Montpelier, VT 05609  
[Ago.highcostprescriptiondrugs@vermont.gov](mailto:Ago.highcostprescriptiondrugs@vermont.gov)

To Whom It May Concern:

Pursuant to 18 V.S.A. § 4637(c), Epizyme Inc., is providing the following information related to the introduction of TAZVERIK<sup>®</sup> (tazemetostat). A notice provided pursuant to 18 V.S.A. § 4637(b) was submitted on January 31, 2020. Pursuant to 18 V.S.A. § 4637(d), Epizyme has limited the information reported below to that which is in the public domain or publicly available.

1. There are no marketing or pricing plans that are in the public domain or publicly available. Marketing activities that support the launch of TAZVERIK<sup>®</sup> are designed to raise awareness and understanding with healthcare providers about the approved indication, efficacy and safety data contained within the medicine's FDA approved label.

Epizyme is committed to innovation and ensuring availability of its product to those patients in need. Epizyme focused its price determination on the value offered to patients, physicians and payers with respect to affordability and access of care. With these value propositions in mind, Epizyme considered numerous factors including; therapeutic analogs, unmet medical needs, therapeutic efficacy, patient tolerability in comparison to the current treatment landscape, the financial resources required to continue discovering new medicines to treat serious diseases and patient access. These considerations focused Epizyme's commitment within the oncology treatment community and informed the organization on its product value determination.

2. No information regarding the volume of patients who may be prescribed TAZVERIK is in the public domain or publicly available, however it is believed there are approximately 800 patients living in the United States with epithelioid sarcoma.
3. TAZVERIK<sup>®</sup> was granted Priority Review by the U.S. Food and Drug Administration on July 22, 2019.
4. TAZVERIK<sup>®</sup> was developed by Epizyme, Inc. and is not an acquired product.

Epizyme provides this report consistent with its understanding and interpretation of 18 V.S.A §4637 and its provisions. In providing this report, Epizyme does not waive any rights, claims or legal challenges with respect to 18 V.S.A § 4637 and related legislation or any implementing regulations thereof.



Thank you,

A handwritten signature in black ink, appearing to read 'John Cosgriff'.

John Cosgriff, Esq.  
Director, Compliance

**Epizyme**

400 Technology Square, 4<sup>th</sup> floor, Cambridge, MA 02139  
617-401-0735